CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the top 10 largest cord blood banks in the world. CryoHoldco is now seven times larger than any other stem cell bank in Latin America with over 275,000 stem cell units in storage.
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
The Generate Life Sciences Family of Companies Grows With the Addition of the Cell Care Group of Cord Blood Banks
The acquisition provides the companies with shared scientific knowledge and resources, leading to a stronger foundation for advancing newborn stem cell research.
LOS ANGELES, June 2, 2021 — Generate Life Sciences (Generate) today announced that it has acquired the Cell Care international cord blood banking group (Cell Care), which comprises Cell Care in Australia, along with Insception Lifebank and Cells for Life in Canada.* [Read more…]
How the MSC Market is Coming of Age in 2021
Mesenchymal stem cells (MSCs) are of intense therapeutic interest because they represent a population of cells that have the potential to treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research. [Read more…]
Investor Demand for Cord Blood, Cord Tissue, and Perinatal Products
Did you know that more than 70% of the global cord blood market is controlled by the world’s 15 largest cord blood banking operators? It’s an incredible figure, but true.
The reason for this is that massive cord blood industry consolidation has happened in recent years, particularly within the U.S, Europe, Asia, and Latin America, with: [Read more…]
Cryo-Cell Enters Exclusive Agreement for Duke University’s Cord Blood and Tissue Assets
Cryo-Cell International, Inc. (symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells, has entered into a collaborative license agreement with Duke University. The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.
MIAMI, Feb. 26, 2021 — Cryo-Cell plans to explore, test, and administer these treatments to patients with conditions for which there are limited FDA approved therapies, including cerebral palsy, autism, multiple sclerosis and COVID-19. [Read more…]
